The drugmakers designed their updated vaccines to target the omicron subvariant XBB.1.5, which is slowly declining nationwide. But health experts and initial data suggest that the new shots will still be effective against Eris, or EG.5, and other widely circulating variants – all of which are descendants of omicron.

“I think that these vaccines will provide very substantial protection against EG.5. Maybe just a little bit of loss, but it’s nothing that I’m very concerned about,” Dr. Mark Mulligan, director of the NYU Langone Vaccine Center, told CNBC. “It looks like we’re going to be OK.”

All three companies are still waiting for the Food and Drug Administration to approve their vaccines, meaning those jabs won’t be available to the public for a month or so. The Centers for Disease Control and Prevention also has to decide which Americans should get the shots and how often.

In April of this year, Spanish athlete Beatriz Flamini emerged into the light after a 500-day stay in a cave. Her descent underground is probably the longest undertaken by a long stretch. Flamini says she lost all sense of time on the 65th day. But can she really be sure it was the 65th day? By way of comparison, in 1962 France’s Michel Siffre surfaced from the Scarasson chasm in Italy after spending what he thought was 33 days there. In fact, he spent 58 days underground.

How can isolated human beings keep regular track of time, even when they’re disconnected from their surrounding environment? Quite simply, because biological rhythms are at the heart of life, regulating it all the way from the molecular level up to that of the entire body. These include not only our sleep/wake cycles, but also body temperature, hormones, metabolism and the cardiovascular system, to name but a few.

And these rhythms have many repercussions, not least in terms of public health. Indeed, a number of diseases are episodic—for example, asthma is more severe at night, while cardiovascular accidents are more frequent in the morning. Another example is shift work, which disconnects people from their environment. It may be associated with an increased risk of cancers in workers, prompting the WHO to label it as a probable carcinogen.

Antipsychotic drugs treat incredibly vulnerable patients. Maintaining a treatment regimen is difficult for many patients, but not taking the medication is associated with a higher risk of poor health outcomes. These drugs are also very powerful with strong side effects, and blood tests are often used to calibrate a patient’s dosage and confirm that they are taking the recommended dose.

However, blood tests are invasive and potentially uncomfortable. Scientists have now discovered a way to test the levels of common antipsychotic drugs in the sweat from patients’ fingerprints, offering a quicker, more comfortable, and more convenient alternative to blood draws for patient monitoring.

“Our test offers patients a quick and dignified way of showing commitment to antipsychotic treatment,” said Katherine Longman of the University of Surrey, first author of the study in Frontiers in Chemistry. “This non-invasive approach can also be adapted to fit other therapeutic regimes.”

Britain’s state-run national health service will be the first in the world to offer an injection that treats cancer to hundreds of patients in England which could cut treatment times by up to three quarters.

Following approval from the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England said on Tuesday (Aug 29) hundreds of eligible patients treated with the immunotherapy, atezolizumab, were set to have “under the skin” injection, which will free up more time for cancer teams.

“This approval will not only allow us to deliver convenient and faster care for our patients, but will enable our teams to treat more patients throughout the day,” Dr Alexander Martin, a consultant oncologist at West Suffolk NHS Foundation Trust said.

The article titled “Evaluation of OVX836: A Promising Universal Influenza Vaccine Candidate” published in The Lancet presents a comprehensive assessment of OVX836, a novel influenza vaccine candidate targeting the nucleoprotein of influenza A virus. Authored by a team of researchers led by IL-R at CEVAC Clinical Unit and Laboratory, the study aims to investigate the safety, immunogenicity, and potential efficacy of OVX836 at different doses, shedding light on its potential as a universal influenza vaccine.

Influenza remains a significant global health concern, with seasonal epidemics and occasional pandemics causing substantial morbidity and mortality. Current influenza vaccines primarily focus on the viral surface protein hemagglutinin, but their efficacy is limited by antigenic variation and the emergence of new strains. Current vaccines are developed for the season based on what strains were prominent in the last season. Additionally, vaccine efficacies can vary from season to season. OVX836 takes a different approach by targeting the highly conserved nucleoprotein, which plays a crucial role in the influenza virus life cycle.

OVX836 elicited a robust immune response, characterized by significant increases in nucleoprotein-specific CD4 and CD8 T-cell responses, as well as the production of anti-nucleoprotein IgG antibodies. The magnitude of these immune responses displayed a dose-dependent relationship, with higher doses of OVX836 leading to stronger immune reactions. Of particular interest was the induction of a CD8 T-cell response, a rare achievement for influenza vaccines and a crucial component of comprehensive immune protection.